New data presented on Baxter's AMIA APD system also indicated how a clinic was able to provide more efficient training for patients, helping those on AMIA to go home at least one day sooner than on the legacy APD system. These conclusions were reached in a retrospective review of patients on AMIA and the Baxter HOMECHOICE system by the Icahn School of Medicine, Mount Sinai, Renal Division in New York.About AMIA and HOMECHOICE CLARIA with SHARESOURCE AMIA was designed to allow patients to administer their own PD therapy in the home setting with intuitive features, such as voice guidance, a touchscreen control panel and the SHARESOURCE remote patient management platform. AMIA also is up to 40 percent smaller and 30 percent lighter than other cyclers on the market, and features a folding design when the touch screen is not in use 3,4. SHARESOURCE allows healthcare providers to securely view their patients' recently completed home dialysis-related treatment data that is automatically collected after each PD session. Healthcare providers can then act on this information by remotely adjusting their patients' home device settings without requiring them to travel to the clinic. AMIA with SHARESOURCE is available in the United States and is currently being used by more than 1,000 ESRD patients to manage therapy. The SHARESOURCE remote patient management platform is also available outside the United States on Baxter's HOMECHOICE CLARIA system, which is currently being used by more than 1,300 patients to conduct home therapy. Baxter's SHARESOURCE telehealth platform recently reached a milestone of helping healthcare providers manage about 200,000 PD treatments performed in patients' homes with either AMIA or HOMECHOICE CLARIA. Rx Only. For safe and proper use of the devices mentioned herein, refer to the complete instructions in the Operator's Manual. About Baxter International Inc. Baxter provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile IV solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics; and pharmacy automation, software and services. The company's global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. Baxter's employees worldwide are building upon the company's rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.
This release includes forward-looking statements concerning Baxter's AMIA and HOMECHOICE CLARIA APD systems and the SHARESOURCE remote patient management platform, including anticipated benefits associated with their use. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; product quality, manufacturing or supply issues; patient safety issues; changes in law and regulations; breaches or failures of the company's information technology systems; and other risks identified in Baxter's most recent filing on Form 10-K and other SEC filings, all of which are available on Baxter's website. Baxter does not undertake to update its forward-looking statements.Baxter, Amia, HomeChoice Claria and Sharesource are registered trademarks of Baxter International Inc. 1 Kolesnyk, Inna et al. Time-Dependent Reasons for Peritoneal Dialysis Technique Failure and Mortality. Peritoneal Dialysis International. 2010. Vol. 30. 170-177. 2 Data on file, Baxter International, 2016. 3 Amia Automated PD System Patient Guide. Baxter Healthcare Corporation. Deerfield, IL. 4 HomeChoice and HomeChoice PRO APD Systems Patient At-Home Guide. Baxter Healthcare Corporation. Deerfield, IL.